Big Pharma loves to talk about innovation. But the real competitive edge in drug development isn’t just molecules—it’s timing. And timing, in pharma, is governed by one thing most investors and operators still treat like an afterthought: drug patent da…

Patent cliffs don’t just hit revenue—they hit supply chains.
When a blockbuster drug’s patent expires, the market doesn’t simply “get cheaper.” It gets messier: new entrants, shifting pricing dynamics, changing lead times, evolving regulatory pathway…

Generic drug makers are facing a quiet squeeze—and it’s not just one problem. It’s a stack of pressures hitting margins from every angle: pricing dynamics, regulatory friction, supply-chain risk, litigation uncertainty, contracting leverage, and the ri…

Branded pharma’s revenue model is under siege—and the threats aren’t theoretical. They’re already showing up in the numbers, in formularies, in pharmacy benefit manager (PBM) decisions, and in the quiet but relentless erosion of “protected” market shar…

Generic drug competition isn’t “just” about filing ANDAs. It’s about timing, intelligence, and decoding the FDA’s Orange Book.
If you’ve ever wondered why some generic manufacturers seem to move faster—or win market entry more cleanly—than others, the …

Biopharma is hiring for “IP,” but most teams still don’t hire for the org chart behind the patents.
That mismatch is expensive—financially, operationally, and strategically. If you’ve ever watched a brilliant IP hire struggle to translate claim scope i…

The Generic Cliff Doesn’t Arrive—It’s Engineered Around.
If you’ve ever wondered why some pharma companies seem to “beat” expiring patents while others get hit with a sudden revenue drop, the answer is rarely luck. It’s strategy—often executed years …

Drug companies don’t just invent medicines—they build legal fortresses. And when those fortresses surround biologic blockbusters, patients, payers, and competitors can get stuck waiting years for meaningful price relief and innovation.
Here’s the uncom…

AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Most people think patent risk is something you deal with after you’ve already committed—after the acquisition, after the launch plan, after the budget is locked. But in pharma, that…

Most teams hunt patents too late. The real advantage is finding design-around opportunities before the market even notices.
If you’re building a pipeline, launching a product, or investing in generics/biosimilars, you already know the obvious: formulat…